• Shuo Han, Yuan Hou, Huaman Liu, and Quanlin Zhao.
• Zibo Branch of the 960th Hospital of the Chinese People's Liberation Army, Zibo, China.
• Medicine (Baltimore). 2022 Nov 25; 101 (47): e31269e31269.

BackgroundDiabetic cardiomyopathy, secondary to diabetes, is the main cause of death in patients with diabetes. In China, traditional Chinese medicine has achieved good performance in treating diabetic cardiomyopathy. However, to date, no systematic review or meta-analysis has been published on the treatment of diabetic cardiomyopathy by traditional Chinese medicine.MethodsThis study strictly followed the preferred guidelines for systematic review. Two researchers searched seven databases: EMbase, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database, and WANFANG Database. The retrieval time limit ranged from the establishment of the database to August 2022. All clinical randomized controlled trials that met the inclusion and exclusion criteria were included in this study. Statistical analysis was performed using RevMan 5.3.ResultsThis study analyzed the clinical efficacy and safety of traditional Chinese medicine in the treatment of diabetic cardiomyopathy.ConclusionThe results of this study provide evidence-based medical evidence for the clinical use of traditional Chinese medicine in the treatment of diabetic heart disease in the future.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…